Analysis of Business Integration for Zuoli Pharmaceutical's Acquisition of Yingda Futures

Based on my search and analysis, currently

1. The transaction may not have occurred yet
   : The acquisition may still be in the negotiation stage and has not been officially announced to the public
2. The information may be inaccurate
   : There may be misinformation or misunderstanding
3. Time scope issue
   : If this is a recent transaction, it may not have been reported by mainstream financial media yet

• A pharmaceutical enterprise focusing on drug manufacturing
• Main business: Production of characteristic and generic drugs
• Current market capitalization: Approximately $3.43 billion
• Price-to-earnings ratio: 14.89 times
• Return on equity: 17.53%
• Net profit margin: 28.76%

If we assume such an acquisition exists, the expected business synergies include:

• Futures tools can be used for raw material price risk management
• Enhance the efficiency of enterprise fund utilization and investment returns

• Expand the boundary of financial services for pharmaceutical enterprises
• Explore the innovative model of “Pharmaceutical + Finance”

• Use the futures market to hedge against raw material price fluctuation risks
• Establish a more comprehensive enterprise risk management system

Due to the lack of specific transaction information, it is recommended:

1. Pay attention to official announcements
   : Regularly check the official announcements and investor relations information of the two companies
2. Verify information sources
   : Confirm the reliability and accuracy of the news
3. Consult professionals
   : If investment decisions are needed, it is recommended to consult professional financial advisors

[0] Jinling API - Zuoli Pharmaceutical (603811.SS) Company Profile and Financial Data (https://www.jinlingai.com/data)